John Fesko Sells 669 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 669 shares of Natera stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the sale, the insider now directly owns 114,142 shares in the company, valued at approximately $18,217,063.20. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $160.26 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm has a market cap of $21.16 billion, a PE ratio of -91.06 and a beta of 1.63. The firm’s 50 day simple moving average is $150.92 and its 200-day simple moving average is $128.12. Natera, Inc. has a one year low of $58.53 and a one year high of $175.63.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period in the previous year, the company posted ($0.95) EPS. Natera’s revenue was up 63.9% on a year-over-year basis. As a group, equities analysts predict that Natera, Inc. will post -1.61 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on NTRA shares. JPMorgan Chase & Co. boosted their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Robert W. Baird upped their target price on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Piper Sandler lifted their price target on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Leerink Partners upped their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $152.67.

Institutional Trading of Natera

A number of hedge funds have recently added to or reduced their stakes in the business. Covestor Ltd raised its holdings in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. GAMMA Investing LLC raised its stake in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares in the last quarter. CIBC Asset Management Inc boosted its position in Natera by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 111 shares in the last quarter. RiverPark Advisors LLC boosted its position in Natera by 3.5% during the 3rd quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock valued at $425,000 after acquiring an additional 112 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC increased its holdings in shares of Natera by 5.4% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after acquiring an additional 135 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.